PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 22, 2026Expert Opinion on Biological Therapy0 citations

Inebilizumab, a novel anti-CD19 antibody for treatment of IgG4-related disease: an overview from clinical trials

View Full Paper
YTYoshiya Tanaka

Key Points

  • This overview examines the role of inebilizumab in treating IgG4-related disease and its effectiveness compared to traditional therapies.
  • Reviewed literature on inebilizumab and clinical trial results.
  • Analyzed current treatment strategies for IgG4-RD.
  • Assessed the safety and efficacy of inebilizumab compared to glucocorticoids.
  • Inebilizumab shows promise in reducing organ damage associated with IgG4-RD.
  • Clinical trials indicate improved efficacy and safety profiles over traditional treatments.
  • Targeted therapies like inebilizumab may address limitations of glucocorticoids.

Abstract

This article provides an overview of advances in treatment strategies for IgG4-RD, shedding light upon the characteristics of inebilizumab and results of the clinical trials. Various targeted therapies under the development are expected to overcome limitations in safety and efficacy of glucocorticoids and to reduce risk of organ damage and fibrosis.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Yoshiya Tanaka (2026) studied this question.

synapsesocial.com/papers/699a9d7a482488d673cd35e0https://doi.org/10.1080/14712598.2026.2634052
Ask AI
Helpful
Bookmark
Share
View Full Paper